Advanced Skin Cancers Coverage from Every Angle
Editor:
Soo Park, MD
Advertisement
Advertisement

Available Clinical Trials

A multicenter, randomized, double-blinded, placebo-controlled, Phase 3 trial of adjuvant Avelumab in Merkel cell carcinoma patients with lymph node metastases
A Phase 1 Study Of Pre-Operative Cemiplimab For Patients With Recurrent Cutaneous Squamous Cell Carcinoma
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab vs placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
Anatomically Directed Therapy for Merkel Cell Carcinoma in the Modern Era
Double-Blind Study of Adjuvant Cemiplimab Vs Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Histologic, Molecular, and Genetic Prognostic Factors in Merkel Cell Carcinoma
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Pembrolizumab Vs Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
SPIND - Fecal microbiota transplant for immunotherapy-resistant metastatic Merkel cell carcinoma
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Study of Adjuvant Cemiplimab Vs Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.